Table 3.
Results of WOMAC measure in E, MT, and C groups of participants.
| Variable | Group | Before | After | p-Value3 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Median | Range | p-Value1 | Mean ± SD | Median | Range | p-Value2 | |||
| WOMAC | E | 45.9 ± 13.7 a | 42.0 | 19.0–65.0 | <0.01 | 39.7 ± 12.8 a | 45.0 | 12.0–58.0 | <0.01 | <0.01 |
| MT. | 46.3 ± 19.0 b | 44.0 | 2.0–81.0 | 40.1 ± 21.7 b | 33.0 | 1.0–84.0 | 0.01 | |||
| C | 19.3 ± 17.6 a,b | 13.0 | 2.0–78.0 | 18.4 ± 18.6 a,b | 12.0 | 1.0–75.0 | 0.11 * | |||
p-value1—the comparison of intergroup WOMAC pre-treatment (Kruskal-Wallis test or Mann-Whitney U test); p-value2—the comparison of intergroup WOMAC post-treatment (Kruskal-Wallis test or Mann-Whitney U test); p-value3—the comparison of intragroup WOMAC pre- and post-treatment (dependent t-student test or * Wilcoxon signed ranked test); a,b—posthoc analysis.